Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

This study has been completed.
Information provided by (Responsible Party):
Janssen Research & Development, LLC Identifier:
First received: June 7, 2011
Last updated: November 23, 2015
Last verified: November 2015
This study (UNITI-2) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to a placebo over 8 weeks in patients with moderately to severely active Crohn's disease.

Condition Intervention Phase
Crohn's Disease
Inflammatory Bowel Disease
Drug: Group 3: ustekinumab approximately 6 mg/kg
Drug: Group 1: Placebo
Drug: Group 2 ustekinumab 130 mg
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)

Resource links provided by NLM:

Further study details as provided by Janssen Research & Development, LLC:

Primary Outcome Measures:
  • Clinical Response [ Time Frame: Week 6 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Clinical remission [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
  • Clinical improvement/response [ Time Frame: Study visits through Week 8 ] [ Designated as safety issue: No ]

Enrollment: 638
Study Start Date: July 2011
Study Completion Date: October 2014
Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 001
Group 1: Placebo Form=solution for injection route=intravenous use in a single dose.
Drug: Group 1: Placebo
Form=solution for injection, route=intravenous use, in a single dose.
Experimental: 002
Group 2 ustekinumab 130 mg Type=exact unit=mg number=130 form=solution for injection route= intravenous use in a single dose.
Drug: Group 2 ustekinumab 130 mg
Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.
Experimental: 003
Group 3: ustekinumab approximately 6 mg/kg Type=range unit=mg/kg number=6 form=solution for injection route= intravenous use in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg) 390 mg (weight > 55 kg and <= 85 kg) and 520 mg (weight > 85 kg).
Drug: Group 3: ustekinumab approximately 6 mg/kg
Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg), 390 mg (weight > 55 kg and <= 85 kg), and 520 mg (weight > 85 kg).

Detailed Description:
This study (CNTO1275CRD3002 or "UNITI-2") examines ustekinumab (an antibody medication that inhibits the inflammatory proteins IL-12 and IL-23) versus a placebo (otherwise identical except without the ustekinumab antibody) given intravenously (by an IV) in adults with moderately to severely active Crohn's disease. Ustekinumab (also known as Stelara) is approved as a treatment for the skin condition of moderate to severe plaque-type psoriasis, but this study will examine if ustekinumab can provide benefit in Crohn's disease and also assess for any risks or side effects. Both the positive and negative outcomes of IV placebo versus two different doses of IV ustekinumab will be tracked and compared over eight weeks, in approximately 612 patients who have previously failed or were intolerant to corticosteroids or immunomodulators (methotrexate, azathioprine, or 6-mercaptopurine) or are dependent on corticosteroid medications. Patients enrolling in this study will be assigned to one of the 3 treatment groups by chance (randomly, like rolling dice), and all will receive a single IV administration of study agent at the first study visit (after the screening period), and then will be asked to return for 3 additional visits through Week 8. Patients who complete this study through the Week 8 visit and remain eligible can enter the maintenance study (CNTO1275CRD3003 or "IM-UNITI"), where they will receive additional study agent, including the administration of ustekinumab in patients who receive placebo in this study and have not had improvement in their Crohn's disease. Patients who do not enter the CNTO1275CRD3003 study will have a final safety follow-up visit approximately 20 weeks after they received study agent when they entered into this study at the Week 0 visit. .All patients will receive a single intravenous (IV) administration of study drug (placebo or ustekinumab) at the start of the study.There are 3 treatment groups in this study: Group 1: Placebo; Group 2: ustekinumab 130 mg, Group 3: weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg), 390 mg (weight > 55 kg and <= 85 kg), and 520 mg (weight > 85 kg).

Ages Eligible for Study:   18 Years to 99 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have Crohn's disease of at least 3 months' duration with colitis, ileitis, or ileocolitis, confirmed at some time in the past by radiography, histology, or endoscopy
  • Have active Crohn's disease, defined as a baseline Crohn Disease Activity Index (CDAI) score of >= 220 and <= 450, with confirmation of active inflammation
  • Has failed conventional therapy as demonstrated by having received corticosteroids and/or immunomodulators(ie, AZA, MTX, or 6-MP) at adequate therapeutic doses OR Have a history of failure to respond to or tolerate an adequate course of corticosteroids and/or immunomodulators (ie, AZA, MTX, or 6-MP) at adequate therapeutic doses OR Is corticosteroid dependent or has had a history of corticosteroid dependency AND Has not previously demonstrated failure of or intolerance to 1 or more TNF-antagonist therapies (ie, infliximab, adalimumab, or certolizumab pegol) per study criteria
  • Have screening laboratory test results within protocol-specified parameters

Exclusion Criteria:

  • Patients who have had any kind of bowel resection within 6 months
  • Are pregnant or planning pregnancy (both men and women) while enrolled in the study or for 20 weeks after receiving study agent
  • Patients who have received infliximab, adalimumab or certolizumab pegol < = 8 weeks before the first administration of study drug
  • Patients with certain complications of Crohn's disease that would make it hard to assess response to study drug
  • Patients with a history of or ongoing chronic or recurrent infectious disease
  • Patients who have previously received a biologic agent targeting IL-12 or IL-23, including but not limited to ustekinumab (CNTO 1275) or briakinumab (ABT-874)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01369342

  Hide Study Locations
United States, Arizona
Tucson, Arizona, United States
United States, Arkansas
Little Rock, Arkansas, United States
United States, California
La Jolla, California, United States
Los Angeles, California, United States
San Diego, California, United States
Santa Monica, California, United States
Torrance, California, United States
United States, Colorado
Lone Tree, Colorado, United States
United States, Florida
Boca Raton, Florida, United States
Gainesville, Florida, United States
Jacksonville, Florida, United States
Largo, Florida, United States
Miami, Florida, United States
Naples, Florida, United States
Port Orange, Florida, United States
Winter Park, Florida, United States
United States, Georgia
Athens, Georgia, United States
Atlanta, Georgia, United States
Decatur, Georgia, United States
Macon, Georgia, United States
United States, Idaho
Idaho Falls, Idaho, United States
United States, Illinois
Chicago, Illinois, United States
United States, Iowa
Clive, Iowa, United States
United States, Kansas
Pratt, Kansas, United States
Topeka, Kansas, United States
United States, Kentucky
Crestview Hills, Kentucky, United States
Lexington, Kentucky, United States
Louisville, Kentucky, United States
United States, Louisiana
Baton Rouge, Louisiana, United States
Houma, Louisiana, United States
New Orleans, Louisiana, United States
United States, Maryland
Chevy Chase, Maryland, United States
Columbia, Maryland, United States
Towson, Maryland, United States
United States, Massachusetts
Boston, Massachusetts, United States
Worcester, Massachusetts, United States
United States, Michigan
Ann Arbor, Michigan, United States
Chesterfield, Michigan, United States
Novi, Michigan, United States
Troy, Michigan, United States
Ypsilanti, Michigan, United States
United States, Minnesota
Rochester, Minnesota, United States
United States, Mississippi
Jackson, Mississippi, United States
Ocean Springs, Mississippi, United States
United States, Missouri
Columbia, Missouri, United States
Kansas City, Missouri, United States
Lees Summit, Missouri, United States
Urbana, Missouri, United States
United States, Nevada
Las Vegas, Nevada, United States
United States, New Jersey
Egg Harbor, New Jersey, United States
Marlton, New Jersey, United States
Morristown, New Jersey, United States
United States, New York
Great Neck, New York, United States
New York, New York, United States
Poughkeepsie, New York, United States
United States, North Carolina
Chapel Hill, North Carolina, United States
Charlotte, North Carolina, United States
Raleigh, North Carolina, United States
United States, Ohio
Beavercreek, Ohio, United States
Cincinnati, Ohio, United States
Columbus, Ohio, United States
Mentor, Ohio, United States
United States, Oklahoma
Norman, Oklahoma, United States
Oklahoma City, Oklahoma, United States
Tulsa, Oklahoma, United States
United States, Oregon
Bend, Oregon, United States
Portland, Oregon, United States
United States, Pennsylvania
Malvern, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
United States, South Carolina
Columbia, South Carolina, United States
North Charleston, South Carolina, United States
United States, Tennessee
Germantown, Tennessee, United States
Nashville, Tennessee, United States
United States, Texas
Austin, Texas, United States
Grapevine, Texas, United States
Houston, Texas, United States
Tyler, Texas, United States
United States, Utah
Salt Lake City, Utah, United States
United States, Virginia
Charlottesville, Virginia, United States
Chesapeake, Virginia, United States
Virginia Beach, Virginia, United States
United States, Washington
Bellevue, Washington, United States
Seattle, Washington, United States
United States, Wisconsin
Madison, Wisconsin, United States
Adelaide, Australia
Cairns, Australia
Central Queensland M C, Australia
Concord, Australia
Fremantle, Australia
Garran, Australia
Liverpool, Australia
Malvern, Australia
Parkville, Australia
Brussel, Belgium
Leuven, Belgium
Goiânia, Brazil
Porto Alegre, Brazil
Rio De Janeiro, Brazil
Sao Paulo, Brazil
São Paulo, Brazil
Pleven, Bulgaria
Rousse, Bulgaria
Sofia, Bulgaria
Varna, Bulgaria
Canada, Alberta
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Canada, British Columbia
Vancouver, British Columbia, Canada
Canada, Manitoba
Brandon, Manitoba, Canada
Canada, Ontario
Kingston, Ontario, Canada
London, Ontario, Canada
Toronto, Ontario, Canada
Canada, Quebec
Montreal, Quebec, Canada
Canada, Saskatchewan
Saskatoon, Saskatchewan, Canada
Saskatoon N/A, Canada
Winnipeg N/A, Canada
Osijek, Croatia
Rijeka, Croatia
Zagreb, Croatia
Amiens Cedex 1, France
Bordeaux, France
Caen Cedex 9, France
Lille, France
Paris Cedex 18, France
Paris, France
Rouen, France
Vandoeuvre Les Nancy, France
Berlin, Germany
Bochum, Germany
Frankfurt, Germany
Halle, Germany
Hamburg, Germany
Hannover, Germany
Haßloch, Germany
Heidelberg, Germany
Kiel, Germany
Lÿneburg, Germany
Mannheim, Germany
Minden, Germany
München, Germany
Münster, Germany
Regensburg, Germany
Stade, Germany
Ulm, Germany
Budapest N/A, Hungary
Budapest, Hungary
Békéscsaba, Hungary
Debrecen, Hungary
Gyula, Hungary
Mosonmagyaróvár, Hungary
Pecs, Hungary
Szekesfehervar, Hungary
Szekszard, Hungary
Reykjavik, Iceland
Beer Yaakov, Israel
Haifa, Israel
Jerusalem, Israel
Kfar Saba, Israel
Petah Tikva, Israel
Rehovot, Israel
Tel Aviv, Israel
Chikushino, Japan
Hachioji, Japan
Hamamatsu, Japan
Hirosaki, Japan
Hiroshima, Japan
Kagoshima, Japan
Nishinomiya, Japan
Ohtsu, Japan
Oita, Japan
Osaka, Japan
Sakura, Japan
Sapporo, Japan
Sendai, Japan
Suita-Shi, Japan
Tokyo, Japan
Tsu, Japan
Uruma, Japan
Yokkaichi, Japan
Yokohama, Japan
Yokosuka, Japan
Korea, Republic of
Daegu, Korea, Republic of
Gyeonggi-Do, Korea, Republic of
Seoul, Korea, Republic of
Amsterdam Zuidoost, Netherlands
Amsterdam, Netherlands
Maastricht, Netherlands
Rotterdam, Netherlands
New Zealand
Auckland, New Zealand
Christchurch, New Zealand
Dunedin, New Zealand
Grafton, New Zealand
Hamilton, New Zealand
Hastings, New Zealand
Plenty, New Zealand
Wellington, New Zealand
Bydgoszcz, Poland
Elblag, Poland
Krakow, Poland
Lodz, Poland
Warszawa, Poland
Russian Federation
Moscow, Russian Federation
Novosibirsk, Russian Federation
Belgrade, Serbia
Beograd, Serbia
South Africa
Cape Town, South Africa
Durban, South Africa
Pretoria, South Africa
Madrid, Spain
Sabadell, Spain
Santiago De Compostela, Spain
United Kingdom
Birmingham, United Kingdom
Brighton, United Kingdom
Bristol, United Kingdom
Cambridge, United Kingdom
Gloucester, United Kingdom
Harrow, United Kingdom
Liverpool, United Kingdom
London, United Kingdom
Manchester, United Kingdom
Norwich, United Kingdom
Nottinghamshirecc, United Kingdom
Oxford, United Kingdom
Shrewsbury, United Kingdom
Southampton, United Kingdom
Sponsors and Collaborators
Janssen Research & Development, LLC
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC
  More Information

Responsible Party: Janssen Research & Development, LLC Identifier: NCT01369342     History of Changes
Other Study ID Numbers: CR018418  CNTO1275CRD3002  2010-022759-42 
Study First Received: June 7, 2011
Last Updated: November 23, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Janssen Research & Development, LLC:
moderately to severely active Crohn's Disease

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Colonic Diseases
Pharmaceutical Solutions
Dermatologic Agents processed this record on December 08, 2016